SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,387.05 |
| Enterprise Value ($M) | 2,377.05 |
| Book Value ($M) | 10.00 |
| Book Value / Share | 0.07 |
| Price / Book | 238.71 |
| NCAV ($M) | -647.00 |
| NCAV / Share | -4.78 |
| Price / NCAV | -3.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.02 |
| Return on Assets (ROA) | 0.00 |
| Return on Equity (ROE) | 0.07 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.74 |
| Current Ratio | 0.92 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 796.00 |
| Assets | 1,453.00 |
| Liabilities | 1,443.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1,093.00 |
| Operating Income | 269.00 |
| Net Income | 2.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -315.00 |
| Cash from Investing | -98.00 |
| Cash from Financing | -46.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | SG Americas Securities, LLC | 5.17 | ||
| 13D/A | Two Seas Capital LP | 9.97 | -0.84 | |
| 13G | Scopia Capital Management Lp | 8.40 | ||
| 13G | Morgan Stanley | 7.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,883 | 64,925 | 10.60 | |
| 5,886 | 75,909 | 7.75 | |
| 9,048 | 209,169 | 4.33 | |
| 24,226 | 74,328 | 32.59 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IGMS – IGM Biosciences, Inc. | IMUX – Immunic, Inc. |
| IMVT – Immunovant, Inc. | INNV – InnovAge Holding Corp. |
| INSM – Insmed Incorporated |
Financial data and stock pages provided by
Fintel.io